Drugs / Adrenomedullin
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT06072118 | Jan 2022 → Jan 2023 | cerebral arteriopathy, autosomal dominant, with subcortical infarcts and leukoencephalopathy, type 1 | National Cerebral and Cardiovascular Center, Japan | Completed | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT07451769 | Mar 2026 → Mar 2027 expected | migraine without aura | Danish Headache Center | Not yet recruiting | No outcome recorded |
| — | NCT07059546 | Aug 2025 → May 2028 expected | — | Danish Headache Center | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Adrenomedullin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06072118 ↗ |
| Action | Activate | “can activate both the adrenomedullin receptor” NCT07451769 ↗ |
| Modality | Peptide | “Adrenomedullin, a vasoactive peptide, has angiogenic, vasodilation, anti-inflammatory, and anti-oxidative properties” NCT06072118 ↗ |
| Route | Intravenous | “Adrenomedullin will be administered by intravenous infusion.” NCT07059546 ↗ |